HRP20180330T1 - Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om - Google Patents

Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om Download PDF

Info

Publication number
HRP20180330T1
HRP20180330T1 HRP20180330TT HRP20180330T HRP20180330T1 HR P20180330 T1 HRP20180330 T1 HR P20180330T1 HR P20180330T T HRP20180330T T HR P20180330TT HR P20180330 T HRP20180330 T HR P20180330T HR P20180330 T1 HRP20180330 T1 HR P20180330T1
Authority
HR
Croatia
Prior art keywords
cycloastragenol
hydroxy
compositions
methods
xylopyranoside
Prior art date
Application number
HRP20180330TT
Other languages
English (en)
Inventor
Calvin B. Harley
Allison C. Chin
Tsutomu Akama
Nancy Yuk-Yu Ip
Yung-Hou Wong
David M. Miller-Martini
Original Assignee
Telomerase Activation Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telomerase Activation Sciences, Inc. filed Critical Telomerase Activation Sciences, Inc.
Publication of HRP20180330T1 publication Critical patent/HRP20180330T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)

Claims (5)

1. Izdvojeni spoj formule I: [image] , gdje: X1 je hidroksi ili β-d-ksilopiranozid, X2 je hidroksi ili β-d-glukopiranozid, i X3 je hidroksi; OR1 je hidroksi; i R2 tvori, zajedmo s ugljikom 9, kondenzirani ciklopropilni prsten, a ---- predstavlja jednostruku vezu između ugljika 9 i 11, naznačen time što je u količini djelotvornoj za upotrebu u liječenju infekcije HIV-om.
2. Astragalozid IV 16-on, naznačen time što je u količini djelotvornoj za upotrebu u liječenju infekcije HIV-om.
3. Farmaceutski pripravak, naznačen time što sadrži, u farmaceutski prihvatljivom vehikulumu, spoj koji se bira između astragalozid IV 16-ona, cikloastragenol 6-β-d-glukopiranozida i cikloastragenol 3-β-d-ksilopiranozida.
4. Farmaceutski pripravak, naznačen time što sadrži topikalnu formulaciju izdvojenog spoja koji se bira između cikloastragenola, astragenola, astragalozid IV 16-ona, cikloastragenol 6-β-d-glukopiranozida i cikloastragenol 3-β-d-ksilopiranozida.
5. Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni spoj prisutan u navedenoj formulaciji u koncentraciji od najmanje 0,1% (tež./vol.).
HRP20180330TT 2003-06-23 2018-02-23 Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om HRP20180330T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23
EP04777032.6A EP1644009B1 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
PCT/US2004/020277 WO2005000245A2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity

Publications (1)

Publication Number Publication Date
HRP20180330T1 true HRP20180330T1 (hr) 2018-04-20

Family

ID=33551962

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180330TT HRP20180330T1 (hr) 2003-06-23 2018-02-23 Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om
HRP20190322TT HRP20190322T1 (hr) 2003-06-23 2019-02-18 Pripravci namijenjeni povećavanju aktivnosti telomeraze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190322TT HRP20190322T1 (hr) 2003-06-23 2019-02-18 Pripravci namijenjeni povećavanju aktivnosti telomeraze

Country Status (24)

Country Link
US (3) US7846904B2 (hr)
EP (2) EP2548880B1 (hr)
JP (4) JP5583882B2 (hr)
KR (3) KR20110089887A (hr)
CN (1) CN1809364B (hr)
AP (1) AP2280A (hr)
AU (2) AU2004251753C1 (hr)
BR (1) BRPI0411856A (hr)
CA (1) CA2528483C (hr)
CY (2) CY1119951T1 (hr)
DK (2) DK2548880T3 (hr)
EA (1) EA009442B1 (hr)
ES (2) ES2716528T3 (hr)
HR (2) HRP20180330T1 (hr)
HU (2) HUE043168T2 (hr)
LT (2) LT2548880T (hr)
MX (1) MXPA05013844A (hr)
NZ (1) NZ544191A (hr)
PL (2) PL2548880T3 (hr)
PT (2) PT1644009T (hr)
SI (2) SI1644009T1 (hr)
TR (2) TR201802543T4 (hr)
WO (1) WO2005000245A2 (hr)
ZA (1) ZA200509846B (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
KR20110089887A (ko) 2003-06-23 2011-08-09 제론 코포레이션 텔로머라제 활성을 증가시키기 위한 조성물 및 방법
US9248088B2 (en) * 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (zh) * 2005-09-08 2007-08-29 南京医科大学 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用
CN100384830C (zh) * 2006-01-12 2008-04-30 天津药物研究院 环黄芪醇类衍生物以及用途
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
WO2008054711A2 (en) 2006-10-30 2008-05-08 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
EA021544B1 (ru) * 2007-06-04 2015-07-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Триарильные соединения и фармацевтические композиции, их содержащие
CN101225424B (zh) * 2007-09-13 2013-05-29 天津药物研究院 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
PT2437606T (pt) * 2009-05-18 2016-09-22 Telomerase Activation Sciences Inc Composições e processos para aumentar a atividade da telomerase
US20160081912A1 (en) * 2013-05-15 2016-03-24 Fybrands Corp. Compositions for improving the hair, skin, and nails
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
CN104435371A (zh) * 2014-12-06 2015-03-25 郭亮 一种用于治疗关节炎的药酒
CN104491185A (zh) * 2014-12-06 2015-04-08 郭亮 一种祛风湿药酒及其制备方法
CN104435370A (zh) * 2014-12-06 2015-03-25 王香平 风湿保健酒
KR20160069857A (ko) 2014-12-09 2016-06-17 (주)스피어테크 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법
CN104817610A (zh) * 2015-03-15 2015-08-05 北京化工大学 利用硫酸水解制备环黄芪醇的方法
DK3277799T3 (en) 2015-04-03 2020-12-14 Propagenix Inc Ex vivo proliferation af epithelceller
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106474094A (zh) * 2015-08-31 2017-03-08 南京理工大学 一种环黄芪醇电纺纤维膜及其制备方法
CA2998372A1 (en) 2015-09-11 2017-03-16 Chengkang ZHANG Ex vivo proliferation of epithelial cells
CN106307522A (zh) * 2016-11-06 2017-01-11 谭淞文 一种抗衰老保健品及其制备方法和食用方法
CN106831927B (zh) * 2017-02-07 2018-02-09 江西师范大学 一种黄芪甲苷的合成方法
CN108498521B (zh) * 2017-02-24 2020-05-05 北京大学 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
CN111053782B (zh) 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
KR102635196B1 (ko) 2018-10-17 2024-02-13 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 미백 조성물
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
CN109942663B (zh) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 利用双相酸水解制备环黄芪醇的方法
MX2019006749A (es) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Compuestos activadores de senescencia celular.
KR20210037256A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물
KR20210037257A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물
CN111419854B (zh) * 2020-05-18 2021-03-30 南通大学 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用
CN113480628B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种贵州疣螈多肽tk-cath及其编码基因和应用
CN113968894B (zh) * 2021-11-05 2024-05-28 山西大学 一种用黄芪甲苷降解制备环黄芪醇的方法
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212792A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン類の単離法
JPS6212791A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン、その単離法およびその用途
IT1259645B (it) 1992-04-10 1996-03-25 Solis Srl Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) * 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (fr) * 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (ja) * 1994-02-25 1995-09-12 Pola Chem Ind Inc 動脈硬化抑制剤及びこれを含む食品又は医薬
AT402890B (de) 1994-03-16 1997-09-25 Berbi Gmbh Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
DK0778842T3 (da) * 1994-07-07 2006-03-20 Geron Corp Mammal telomerase
US6162459A (en) * 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) * 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (zh) 1995-08-01 2002-02-20 裴国增 灵芝口服液及其配制方法
US5785977A (en) * 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) * 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) * 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (ja) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd ジンセノサイド類含有hsp47合成抑制剤
CA2645721C (en) 1996-10-01 2015-05-12 Geron Corporation Human telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO1998032454A1 (en) * 1997-01-28 1998-07-30 D'amelio, Frank Centipeda plant extract
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
ATE550010T1 (de) * 1997-09-05 2012-04-15 Procter & Gamble Präparate zur reinigung und konditionierung von haut and haaren mit verbesserter ablagerung von konditionierenden bestandteilen
ATE226064T1 (de) * 1997-09-12 2002-11-15 Procter & Gamble Hautreinigungs- und konditionierungsartikel für haut und haar
EP1045697A2 (en) 1998-01-12 2000-10-25 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) * 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
WO2000008135A1 (en) 1998-08-09 2000-02-17 Board Of Regents, The University Of Texas System Methods and compositions for inhibiting or stimulating telomerase assembly
CA2352486A1 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000204091A (ja) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd 新規ベンゾジオキソ―ル誘導体
JP2000229827A (ja) * 1999-02-05 2000-08-22 Kose Corp 皮膚外用剤
JP2000229834A (ja) * 1999-02-10 2000-08-22 Kanebo Ltd 化粧料
AUPQ127399A0 (en) 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2001258505A (ja) * 2000-03-24 2001-09-25 Fancl Corp 食品組成物
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
CN1452629A (zh) 2000-05-31 2003-10-29 科学技术振兴事业团 含有人参皂甙Rb1的皮肤组织再生促进剂
CN1172677C (zh) * 2000-07-14 2004-10-27 复旦大学附属中山医院 黄芪甲苷在制备药物组合物中的应用
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
AU2001275707A1 (en) * 2000-07-26 2002-02-05 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
US6696094B2 (en) * 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (zh) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 一种抗皮肤过敏的药物组合物及其制法和用途
CN1369276A (zh) * 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP2003089687A (ja) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd 新規ブタジエン誘導体、その製法およびその合成中間体
CN1522248A (zh) 2001-07-03 2004-08-18 田边制药株式会社 新型丁二烯衍生物,制备它的方法及合成它的中间体
US20030108629A1 (en) * 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (zh) * 2001-08-31 2004-09-01 上海中医药大学 具有抗心肌纤维化作用的黄芪皂甙甲
CN1406585A (zh) * 2001-09-07 2003-04-02 中国科学院上海药物研究所 一种治疗病毒性心肌炎的药物组合物
JP2003160497A (ja) * 2001-11-22 2003-06-03 Toshin Kagaku Kk 皮膚外用剤
AU2003212936A1 (en) * 2002-02-04 2003-09-02 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
CN1236803C (zh) 2002-03-20 2006-01-18 郑国芃 一种治疗风湿症的中药
CN1189176C (zh) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 黄芪甲甙组合物及其制备方法
WO2004096251A1 (en) * 2003-03-26 2004-11-11 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
KR20110089887A (ko) 2003-06-23 2011-08-09 제론 코포레이션 텔로머라제 활성을 증가시키기 위한 조성물 및 방법
US9248088B2 (en) * 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
US20070122501A1 (en) * 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Also Published As

Publication number Publication date
JP2011098991A (ja) 2011-05-19
CA2528483A1 (en) 2005-01-06
BRPI0411856A (pt) 2006-08-29
JP5913253B2 (ja) 2016-04-27
US8759304B2 (en) 2014-06-24
JP2007524627A (ja) 2007-08-30
HRP20190322T1 (hr) 2019-04-19
KR20060034237A (ko) 2006-04-21
MXPA05013844A (es) 2006-07-06
KR20110089887A (ko) 2011-08-09
TR201802543T4 (tr) 2018-03-21
EP2548880A2 (en) 2013-01-23
EP2548880B1 (en) 2019-01-09
AU2008249200A1 (en) 2008-12-18
JP5583882B2 (ja) 2014-09-03
JP5841337B2 (ja) 2016-01-13
EA200600076A1 (ru) 2006-08-25
EP1644009B1 (en) 2017-11-29
PT2548880T (pt) 2019-02-27
DK2548880T3 (en) 2019-04-08
KR20130137252A (ko) 2013-12-16
SI2548880T1 (sl) 2019-04-30
AP2280A (en) 2011-10-31
ZA200509846B (en) 2007-04-25
CA2528483C (en) 2012-04-10
SI1644009T1 (en) 2018-04-30
TR201903587T4 (tr) 2019-04-22
CN1809364A (zh) 2006-07-26
US20150093455A1 (en) 2015-04-02
PL2548880T3 (pl) 2019-07-31
EP1644009A4 (en) 2010-04-07
AU2004251753C1 (en) 2009-04-09
LT1644009T (lt) 2018-03-12
ES2716528T3 (es) 2019-06-13
CY1121447T1 (el) 2020-05-29
US20080113925A1 (en) 2008-05-15
NZ544191A (en) 2008-12-24
AU2004251753A1 (en) 2005-01-06
PT1644009T (pt) 2018-02-28
US20110071095A1 (en) 2011-03-24
WO2005000245A3 (en) 2005-05-26
ES2666864T3 (es) 2018-05-08
JP2016041770A (ja) 2016-03-31
CN1809364B (zh) 2010-06-16
JP2014024861A (ja) 2014-02-06
CY1119951T1 (el) 2018-12-12
EP2548880A3 (en) 2013-06-19
EA009442B1 (ru) 2007-12-28
WO2005000245A2 (en) 2005-01-06
LT2548880T (lt) 2019-03-25
US7846904B2 (en) 2010-12-07
AU2004251753B2 (en) 2008-11-20
KR101312389B1 (ko) 2013-09-27
HUE043168T2 (hu) 2019-08-28
EP1644009A2 (en) 2006-04-12
AP2005003474A0 (en) 2005-12-31
KR101465515B1 (ko) 2014-11-26
DK1644009T3 (en) 2018-03-05
HUE036559T2 (hu) 2018-07-30
PL1644009T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
HRP20180330T1 (hr) Pripravci za povećavanje aktivnosti telomeraze i liječenje infekcije hiv-om
CA2464250A1 (en) Kit for the preparation of a pharmaceutical composition
RS50368B (sr) Levodopa/karbidopa/entakapon farmaceutski preparat
SE0001899D0 (sv) New compounds
AU2337197A (en) Cinnamic acid derivatives and their use as integrin antagonists
BG103969A (en) C-4"-substituted macrolide derivatives
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
HUP9903544A2 (hu) Helyileg alkalmazható anesztetikus hatású gyógyszerkészítmény
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
ATE222748T1 (de) Orale zusammensetzung mit verbesserter aufnahme
EP1247456A3 (en) Palatable pharmaceutical compositions for companion animals
MXPA04003192A (es) Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
JP2007510712A (ja) 殺菌組成物ならびにその作製方法および使用方法
CA2450359A1 (en) Dosage regimen and pharmaceutical composition for emergency contraception
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
HUP0400553A2 (hu) Gyógyászati készítmények
BR0111868A (pt) Composições farmacêuticas
WO2004087141B1 (en) Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases
JP2003514025A5 (hr)
WO2005115147A3 (en) Hiv reverse transcriptase inhibitors
DE60139409D1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
ATE151405T1 (de) (7s)-7-(2r)-2-(3-chlorophenyl)-2-hydoxyethylami o-5,6,7,8-tetrahydronaphtalen-2-yloxy essigsäure, ihre pharmazeutisch akzeptablen salze, mit beta-3-adrenergischer agonistischer aktivität und diese enthaltende pharmazeutische zusammensetzungen
DE60005517D1 (de) Kaliumkanal-blockierende mittel